Chrome Plugin Live! Redefine the way you read FinTwit 🚀 Install Now
Quote Panel
Key Metrics
Fundamentals
Relative Strength
ALZ.ST
Sector
Top 5 RS in Group
Symbol | Company | RS | 5-Day Perf. |
|---|---|---|---|
Forecast
Analyst rating
Last analyst upgrade/downgrade
Earnings Growth
YoY
Current
Estimates
Q4.22
N/A
-0.15
vs -0.14
Q1.23
N/A
-0.13
vs -0.13
Q2.23
N/A
-0.10
vs -0.10
Q3.23
N/A
-0.08
vs -0.09
Q4.23
N/A
-0.11
vs -0.15
Q1.24
N/A
-0.11
vs -0.13
Q2.24
N/A
-0.11
vs -0.10
Q3.24
N/A
-0.05
vs -0.08
Q4.24
N/A
-0.07
vs -0.11
Q1.25
N/A
-0.06
vs -0.11
Sales Growth
YoY
Current
Estimates
Q4.22
+25%
3.4M vs 2.7M
Q1.23
-33%
4.7M vs 6.9M
Q2.23
+96%
6M vs 3.1M
Q3.23
+2%
3.3M vs 3.2M
Q4.23
-92%
270K vs 3.4M
Q1.24
-99%
30K vs 4.7M
Q2.24
-100%
NA vs 6M
Q3.24
-100%
NA vs 3.3M
Q4.24
-100%
NA vs 270K
Q1.25
+230%
99K vs 30K
Return on Equity
QoQ
Q2.23
-3%
-0.03
vs -0.04
Q3.23
-3%
-0.03
vs -0.03
Q4.23
-4%
-0.04
vs -0.03
Q1.24
-5%
-0.05
vs -0.04
Q2.24
-5%
-0.05
vs -0.05
Q3.24
-3%
-0.03
vs -0.05
Q4.24
-5%
-0.05
vs -0.03
Q1.25
-5%
-0.05
vs -0.05
Institutionnal Ownership
Quote Panel
Key Metrics
Relative Strength
ALZ.ST
Sector
Top 5 RS in Group
Symbol | Company | RS | 5-Day Perf. |
|---|---|---|---|
Forecast
7644%2026-Revenue
-1172%2026-EPS
32%2026-EBITDA
Analyst rating
Strong Sell
Sell
Buy
Neutral
Strong Buy
Price Target
NaN(-100.00%)
Number of analyst
Last analyst upgrade/downgrade
No Data Available
Alzinova AB (publ), a biopharma company, engages in the development of an active immunotherapy for the treatment of Alzheimer's disease in Sweden. Its lead candidate is ALZ-101, an oligomer-specific vaccine for the treatment of Alzheimer's disease; and ALZ-201, a monoclonal antibody that is used for the treatment of toxic Aß oligomers. The company was founded in 2011 and is based in Mölndal, Sweden.
STO
Unprofitable
Unprofitable
-0.05Â ( -3.21%)
Relative Strenght
Volume Buzz
-85%
Earning Acce
No
Dist 52w H.
65%Fundamentals
P/E Ratio
P/S Ratio
P/B Ratio
Debt/Equity
Net Margin
EPS
How ALZ.ST compares to sector?